Karyopharm Therapeutics (KPTI) Gains from Sales and Divestitures (2013 - 2025)
Karyopharm Therapeutics (KPTI) reported Gains from Sales and Divestitures of $230299.0 for Q4 2025, down 90.55% on a YoY basis from $2.4 million in Q4 2024, and down 90.55% quarter-over-quarter from $2.4 million in Q4 2024.
Karyopharm Therapeutics (KPTI) Gains from Sales and Divestitures (2013 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Gains from Sales and Divestitures for 11 years, with the latest figure at $230299.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Sales and Divestitures fell 90.55% year-over-year to $230299.0; the trailing twelve-month figure through Dec 2025 stood at $230299.0 (down 90.55% YoY), and the FY2025 full-year result was $230299.0, down 90.55% from the prior year.
- Gains from Sales and Divestitures for Q4 2025 stood at $230299.0, down from $2.4 million in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $957.7 million in Q4 2022, with the low at $230299.0 in Q4 2025.
- Historically, Gains from Sales and Divestitures has averaged $192.4 million across 5 years, with a median of $1.1 million in 2023.
- Annual changes were most pronounced in 2022 — Gains from Sales and Divestitures jumped 199323.22% — and 2023, when it plunged 99.89%.
- Karyopharm Therapeutics' Gains from Sales and Divestitures stood at $480249.0 in 2021, then jumped by 199323.22% to $957.7 million in 2022, then sank by 99.89% to $1.1 million in 2023, then jumped by 132.04% to $2.4 million in 2024, then slumped by 90.55% to $230299.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $230299.0 (Q4 2025), $2.4 million (Q4 2024), and $1.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 230,299.00 |
| Dec 31, 2025 | 230,299.00 |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 957.73 Mn |
| Dec 31, 2022 | 957.73 Mn |
| Dec 31, 2021 | 480,249.00 |
| Dec 31, 2021 | 480,249.00 |
| Mar 31, 2018 | 5,000.00 |
| Mar 31, 2018 | 5,000.00 |
| Dec 31, 2017 | 182,496.00 |
| Dec 31, 2017 | 182,496.00 |
| Sep 30, 2017 | 5,300.00 |
| Sep 30, 2017 | 5,300.00 |
| Jun 30, 2017 | 5,300.00 |
| Jun 30, 2017 | 5,300.00 |
| Mar 31, 2017 | 3,225.00 |
| Mar 31, 2017 | 3,225.00 |